Literature DB >> 12504553

Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus.

Johan Lantto1, Jean M Fletcher, Mats Ohlin.   

Abstract

Site I of antigenic domain 2 (AD-2) on human cytomegalovirus glycoprotein B (gB) is poorly immunogenic in both man and mouse and knowledge about antibody repertoires reactive with this epitope is thus limited. Here we have characterized a phage display-derived repertoire of antibody fragments specific for this epitope in terms of antigen recognition, fine-specificity, and virus-neutralizing capacity. Our results show that the functional properties within a closely related repertoire may differ widely and that the effectiveness of the members of the repertoire to neutralize the virus is determined by the fine-specificity and kinetics of the interaction with the antigen. The half-life of the interaction between monomeric antibody fragments and gB seems to be particularly critical for the neutralizing capacity. We also demonstrate that sequence variation within gB allows virus variants to escape at least a part of the AD-2-specific neutralizing antibody repertoire, apparently without preventing antibody binding to the epitope.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504553     DOI: 10.1006/viro.2002.1752

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Advances in the Development of Therapeutics for Cytomegalovirus Infections.

Authors:  Edward Acosta; Terry Bowlin; Jennifer Brooks; Lillian Chiang; Islam Hussein; David Kimberlin; Lawrence M Kauvar; Randi Leavitt; Mark Prichard; Richard Whitley
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

Authors:  Krista M McCutcheon; Julia Gray; Natalie Y Chen; Keyi Liu; Minha Park; Stote Ellsworth; Ralph A Tripp; S Mark Tompkins; Scott K Johnson; Shelly Samet; Lenore Pereira; Lawrence M Kauvar
Journal:  MAbs       Date:  2014-01-08       Impact factor: 5.857

Review 3.  Cytomegalovirus Vaccines: Current Status and Future Prospects.

Authors:  K M Anderholm; C J Bierle; M R Schleiss
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

4.  A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types.

Authors:  Lawrence M Kauvar; Keyi Liu; Minha Park; Neal DeChene; Robert Stephenson; Edgar Tenorio; Stote L Ellsworth; Takako Tabata; Matthew Petitt; Mitsuru Tsuge; June Fang-Hoover; Stuart P Adler; Xiaohong Cui; Michael A McVoy; Lenore Pereira
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

5.  Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain.

Authors:  Adam L Feire; Heidi Koss; Teresa Compton
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-19       Impact factor: 11.205

6.  Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay.

Authors:  Xiaoli Pang; Atul Humar; Jutta K Preiksaitis
Journal:  J Clin Microbiol       Date:  2008-10-29       Impact factor: 5.948

7.  Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Authors:  Ilona Baraniak; Barbara Kropff; Gary R McLean; Sylvie Pichon; Fabienne Piras-Douce; Richard S B Milne; Colette Smith; Michael Mach; Paul D Griffiths; Matthew B Reeves
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

Review 8.  Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.

Authors:  Giuseppe Gerna; Daniele Lilleri
Journal:  Vaccines (Basel)       Date:  2020-04-23

9.  Chimeric Antigen Receptors Targeting Human Cytomegalovirus.

Authors:  Ayub Ali; Flavia Chiuppesi; Minh Nguyen; Mary Ann Hausner; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Felix Wussow; Don J Diamond; Otto O Yang
Journal:  J Infect Dis       Date:  2020-08-04       Impact factor: 5.226

10.  Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases.

Authors:  J Rogers; R J Schoepp; O Schröder; T L Clements; T F Holland; J Q Li; J Li; L M Lewis; R P Dirmeier; G J Frey; X Tan; K Wong; G Woodnutt; M Keller; D S Reed; B E Kimmel; E C Tozer
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.